Exposure to potential cyp450 pharmacokinetic drug-drug interactions among osteoarthritis patients: Incremental risk of multiple prescriptions

Pain Practice

Volumn 11, Issue 4, 2011, Pages 325-336

  Pergolizzi Jr, Joseph V ^a,b,c   Labhsetwar, Sumedha A ^c   Puenpatom, R Amy ^d   Joo, Seongjung ^d   Ben Joseph, Rami ^d   Summers, Kent H ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEMA Research   (United States)

^d Endo Pharmaceuticals   (United States)

Author keywords

Analgesics; CYP450; Drug drug interactions; Opioid; Osteoarthritis

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BUSPIRONE; CODEINE; CYTOCHROME P450; DESIPRAMINE; DEXAMETHASONE; DEXTROMETHORPHAN; DIAZEPAM; DONEPEZIL; DULOXETINE; FENTANYL; FLUOXETINE; HYDROCODONE; LIDOCAINE; METHADONE; NORTRIPTYLINE; ONDANSETRON; OPIATE; OXYCODONE; PAROXETINE; PROMETHAZINE; RISPERIDONE; TRAMADOL; UNINDEXED DRUG; VENLAFAXINE;

ADULT; AGED; ARTICLE; CHRONIC PAIN; COMORBIDITY; DATA BASE; DRUG METABOLISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; POLYPHARMACY; PRESCRIPTION; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE;

EID: 79960159735     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2010.00438.x     Document Type: Article

References (45)

1. Food and Drug Administration. Reports Received and Reports Entered into AERS by Year, as of March 31, 2010. Washington, DC: 2010. Available from: (accessed February 28, 2010).
2. Levine M, Xu S, Gaebel K, etal. Self-reported use of natural health products: a cross-sectional telephone survey in older Ontarians. Am J Geriatr Pharmacother. 2009;7:383-392.
3. Kennedy D, Seely D. Clinically based evidence of drug-herb interactions: a systematic review. Expert Opin Drug Saf. 2010;9:79-124.
4. Smith H, Bruckenthal P. Implications of opioid analgesia for medically complicated patients. Drugs Aging. 2010;27:417-433.
5. Arnstein P. Balancing analgesic efficacy with safety concerns in the older patient. Pain Manag Nurs. 2010;11:S11-S22.
6. Pergolizzi J, Labhsetwar S, Puenpatom R, Joo S, Ben-Joseph R, Summers K. Prevalence of exposure to CYP450 pharmacokinetic drug-drug interactions among patients with chronic low back pain. Pain Pract. 2010; DOI:10.1111/j.1533-2500.2010.00413.x.
7. Kuhlmann J, Muck W. Clinical-pharmacological strategies to assess drug interaction potential during drug development. Drug Saf. 2001;24:715-725.
8. Schuler J, Dückelmann C, Beindl W, Prinz E, Michalski T, Pichler M. Polypharmacy and inappropriate prescribing in elderly internal-medicine patients in Austria. Wien Klin Wochenschr. 2008;120:733-741.
9. Moura C, Acurcio F, Belo N. Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharm Sci. 2009;12:266-272.
10. Hastings S, Schmader K, Sloane R, etal. Quality of pharmacotherapy and outcomes for older veterans discharged from the emergency department. J Am Geriatr Soc. 2008;56:875-880.
11. Soodater J, Sousa M, Boffito M. Drug-drug interactions involving new antiretroviral drugs and drug classes. Curr Opin Infect Dis. 2009;22:18-27.
12. Aparasu R, Baer R, Aparasu A. Clinically important potential drug-drug interactions in outpatient settings. Res Social Adm Pharm. 2007;3:426-437.
13. Centers for Disease Control. Osteoarthritis. Atlanta, GA: Centers for Disease Control and Prevention; Available from: (accessed February 18, 2010).
14. ReportLinker. Stakeholder Insight: Osteoarthritis-Drug Development Lags behind Rising Osteoarthritis Population. Paris, France: ReportLinker; 2009. Available from: (accessed February 18, 2010).
15. Fitzcharles M, Lussier D, Shir Y. Management of chronic arthritis pain in the elderly. Drugs Aging. 2010;27:471-490.
16. Mayo Clinic. Treatments and Drugs: Osteoarthritis. 2010. Available from: (accessed November 28, 2010).
17. Bushardt R, Massey E, Simpson T, Ariail J, Simpson K. Polypharmacy: misleading, but manageable. Clin Interv Aging. 2008;3:383-389.
18. Maggiore R, Gross C, Hurria A. Polypharmacy in older adults with cancer. Oncologist. 2010;15:507-522.
19. Dwyer L, Han B, Woodwell D, Rechtsteiner E. Polypharmacy in nursing home residents in the United States: results of the 2004 National Nursing Home Survey. Am J Geriatr Pharmacother. 2010;8:63-72.
20. Elseviers M, Stichele RV, Bortel LV. Drug utilization in Belgian nursing homes: impact of residents' and institutional characteristics. Pharmacoepidemiol Drug Saf. 2010;19:1041-1048.
21. Salazar J, Poon I, Nair M. Clinical consequences of polypharmacy in elderly: expect the unexpected, think the unthinkable. Expert Opin Drug Saf. 2007;6:695-704.
22. Hayes B, Klein-Schwartz W, Barrueto F Jr. Polypharmacy and the geriatric patient. Clin Geriatr Med. 2007;23:371-390.
23. Hovstadius B, Astrand B, Petersson G. Assessment of regional variation in polypharmacy. Pharmacoepidemiol Drug Saf. 2010;120:733-741.
24. Hajjar E, Cafiero A, Hanlon J. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5:314-316.
25. Goldberg R, Mabee J, Chan L, Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 1996;14:447-450.
26. Viktil K, Blix H, Moger T, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol. 2006;63:187-195.
27. Peng C, Glassman P, Marks I, Fowler C, Castiglione B, Good C. Retrospective drug utilization review: incidence of clinically relevant potential drug-drug interactions in a large ambulatory population. J Manag Care Pharm. 2003;9:513-522.
28. Dickson M, Bramely T, Kozma C, Doshi D, Rupnow M. Potential drug-drug interactions with antiepileptic drugs in Medicaid recipients. Am J Health Syst Pharm. 2008;65:1720-1726.
29. Solberg L, Hurley J, Roberts M, etal. Measuring patient safety in ambulatory care: potential for identifying medical group drug-drug interaction rates using claims data. A J Manag Care. 2004;10(11 Pt 1):753-759.
30. Albert S, Colombi A, Hanlon J. Potentially inappropriate medications and risk of hospitalization in retirees. Drugs Aging. 2010;27:407-415.
31. Schneitman-McIntire O, Farnen T, Gordon N, Chan J, Toy W. Medication misadventures resulting in emergency department visits at and HMO medical center. Am J Health Syst Pharm. 1996;53:1416-1422.
32. Malone D, Hutchins D, Haupert H, etal. Assessment of potential drug-drug interactions with a prescription claims database. Am J Health Syst Pharm. 2005;62:1983-1991.
33. Taheri E, Afashari R, Nazemian L. Population-based severity, onset, and type of drug-drug interactions by prescription. Methods Find Exp Clin Pharmacol. 2010;32:237-242.
34. Association AM. Osteoarthritis physician performance measurement set; 2003. Available from: (accessed February 25, 2010).
35. Holmquist G. Opioid metabolism and effects of cytochrome P450. Pain Med. 2009;10:S20-SS9.
36. Becker M, Kallewaard M, Caspers P, Visser L, Luefkens H, Stricker B. Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf. 2007;16:641-651.
37. Haider S, Johnell K, Weitoft G, Thorslund M, Fastbom J. The influence of educational level on polypharmacy and inappropriate drug use: a register-based study of more than 600, 000 older people. J Am Geriatr Soc. 2009;57:62-69.
38. Viktil K, Blix H, Moger T, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol. 2007;63:187-195.
39. Zhang K, Young C, Berg J. Administrative claims analysis of the relationship between warfarin use and risk of hemorrhage including drug-drug and drug-disease interactions. J Manag Care Pharm. 2006;12:686-687.
40. Charlson M, Szatrowski T, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245-1251.
41. Bonnabry P, Despont-Gros C, Grauser D, etal. A risk analysis method to evaluate the impact of a computerized provider order entry system on patient safety. J Am Med Inform Assoc. 2008;15:453-460.
42. Rosse FV, Maat B, Rademaker C, Vught AV, Egberts A, Bollens C. The effect of computerized physician order entry on medication prescription errors and clinical outcome in pediatric and intensive care: a systematic review. Pediatrics. 2009;123:1184-1190.
43. Qato D, Alexander G, Conti R, Johnson M, Schumm P, Lindau S. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300:2867-2878.
44. Jankel C, Speedie S. Detecting drug interactions: a review of the literature. DICP. 1990;24:982-989.
45. Armstrong S, Cozza K. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part I. Psychosomatics. 2003;44:167-171.